DYNMEDIUM SIGNALFINANCIAL10-K

DYN significantly strengthened its balance sheet with cash doubling to $893M while extending commercialization timeline to 2027 and substantially increasing R&D spending.

The company appears to have completed a major funding round that dramatically improved its financial position, providing runway for expanded development programs. However, the extended commercialization timeline and 42% increase in R&D expenses signal either program delays or more ambitious development plans that will burn through cash faster.

Comparing 2026-03-02 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

DYN's financial position strengthened dramatically with cash more than doubling to $893M and stockholders' equity increasing 54% to $972M, indicating successful capital raising. However, the company is burning cash significantly faster with R&D expenses up 42% to $398M and operating cash flow declining 38% to -$403M, while net losses widened to $446M. The substantially increased total liabilities of $215M (up 250%) alongside the cash increase suggests the funding may have involved debt or complex financial instruments rather than pure equity.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+249.9%
$61.4M$214.8M

Liabilities grew 249.9% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
+105.2%
$435.4M$893.4M

Cash position surged 105.2% — strong cash generation or capital raise providing significant financial cushion.

Total Assets
Balance Sheet
+71.7%
$691.2M$1.2B

Asset base grew 71.7% — expansion through organic growth, acquisitions, or capital deployment.

Current Assets
Balance Sheet
+70.9%
$659.3M$1.1B

Current assets grew 70.9% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+54.3%
$629.8M$972.1M

Equity base grew 54.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

R&D Expense
P&L
+41.6%
$281.4M$398.3M

R&D investment increased 41.6% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-40.6%
-$317.4M-$446.2M

Net income declined 40.6% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-37.9%
-$292.4M-$403.2M

Operating cash flow fell 37.9% — earnings quality concerns; investigate working capital changes and non-cash items.

Operating Income
P&L
-36.1%
-$343.9M-$468.2M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Liabilities
Balance Sheet
+19.8%
$42.3M$50.6M

Current liabilities rose 19.8% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-02
PRIOR — 2025-02-27
ADDED
We do not expect to have a product candidate ready for commercialization at least until 2027, if ever.
Overview We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
Our proprietary FORCE platform is designed to leverage the transferrin receptor 1, or TfR1, to deliver targeted therapeutics to muscle tissue and the central nervous system, or CNS.
The FORCE platform utilizes an antigen-binding fragment antibody, or Fab, targeting TfR1 conjugated to a payload that we rationally design to target the genetic basis of the disease we are seeking to treat.
In addition, we plan to expand our portfolio through development efforts focused on diseases involving the CNS, rare skeletal muscle diseases, and cardiac and metabolic muscle diseases, including some with larger patient populations.
+7 more — sign up free →
REMOVED
As a result, it will be at least a couple of years before we commercialize a product candidate, if ever.
Overview We are a clinical-stage neuromuscular disease company focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases.
Leveraging the modularity of our FORCE platform, we are developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS.
Our proprietary FORCE platform therapeutics consist of a payload that we rationally design to target the genetic basis of the disease we are seeking to treat, a linker and an antigen-binding fragment, or Fab, that we attach to the payload using the linker.
In addition, we plan to expand our portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases, including some with larger patient populations, and diseases involving the CNS.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →